North Korea bans drug sales in markets

17 December 2007

North Korea's authorities have cracked down on what are termed "capitalist trends in the market," by seizing medicines that were sold in markets, according to the Daily NK, which is critical of the hardline Communist regime. Most of the products confiscated in a series of raids over a three-month period were from neighboring China and South Korea, which allegedly included substandard or counterfeit drugs. The crackdown took place in August to October 2006, but has only now been reported outside North Korea.

Private trade formally prohibited

According to the report, the cost of Chinese-made aspirin has increased about 50%, that of an antidiarrheal drug 100% and penicillin around two thirds. Previously, the North Korean government had formally prohibited private sales of drugs, although these were reportedly not rigorously enforced, in part due to problems in ensuring medical supplies in state-run facilities.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight